Prostaglandin Analog Compounds for Ocular Hypertension
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for glaucoma, particularly ocular hypertensive conditions, face challenges in effectively managing intraocular pressure due to limitations in existing ocular hypotensive agents, with a need for more potent and targeted therapeutic options.
Innovation Solution
Development of specific compounds with structures that include organic acid functional groups, amides, esters, or tetrazolyl functional groups, which act as bioisosteres of carboxylic acids, to inhibit HCV NS3 protease and potentially target ocular hypertension by mimicking prostaglandins for glaucoma management.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If traditional topical β-adrenoreceptor antagonists are used to treat glaucoma, then intraocular pressure can be reduced, but the treatment lacks potency and metabolic stability compared to newer therapeutic options
Solution Approach 1:
The patent applies parameter changes by modifying the chemical structure of prostaglandin analogs through systematic variation of substituents at positions 1, 2, 3, 4, and 5 of the cyclopentane ring, as well as modifications to the side chains. This includes changing functional groups (e.g., hydroxyl, carboxylic acid, ester, amide), altering carbon chain lengths, and introducing different aromatic or heteroaromatic groups. These structural parameter changes aim to optimize both the potency and metabolic stability of the compounds while maintaining their ocular hypotensive efficacy.
2Reliability
If prostaglandin derivatives are used for glaucoma management, then ocular hypotensive effect is achieved, but metabolic stability is insufficient
Solution Approach 1:
The patent employs parameter changes to enhance metabolic stability by modifying key structural parameters of the prostaglandin core. Specifically, the invention explores different substitution patterns on the cyclopentane ring, varies the oxidation states of carbon atoms (e.g., introducing carbonyl groups at position 3), and modifies the ester or amide groups at positions 1 and 5. These parameter modifications are designed to protect against metabolic degradation while preserving the bioactivity necessary for reducing intraocular pressure.
3Adaptability or versatility
If existing ocular hypotensive agents are used, then treatment of ocular hypertension is possible, but more potent and targeted therapeutic options are needed
Solution Approach 1:
The patent applies local quality by introducing specific functional groups and substituents at defined positions on the prostaglandin molecular framework. For example, the introduction of electron-withdrawing or electron-donating groups at specific ring positions, the placement of hydroxyl groups at particular locations, and the selection of specific aromatic or heteroaromatic substituents all create localized chemical environments that enhance target binding affinity and selectivity. This localized structural optimization enables more targeted and potent therapeutic action.
Solution Approach 2:
The patent employs composite material principles by combining the prostaglandin core structure with diverse substituent moieties to create composite molecular architectures. The final compounds represent composites of the cyclopentane ring system, various side chains (including aromatic and heteroaromatic groups), and functional groups (esters, amides, carboxylic acids). This composite approach allows for fine-tuning of both potency and targeted activity by selecting appropriate combinations of structural elements.
Data Source
AI summary
A compound having a structureis disclosed herein. Compositions, medicaments, and therapeutic methods related thereto are also disclosed.